Pegvisomant
Somavert · B2036-PEG
A pegylated growth hormone receptor antagonist approved for acromegaly. It blocks the receptor rather than the hormone, which is the opposite mechanism to every secretagogue in this category, and it is the reason IGF-1 rather than GH is used to follow the response.
Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.
Regulatory status
FDA approved
The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
~60-138 h, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied as a lyophilized powder in a single-dose vial with its own diluent; refrigerated per its label.
References
- FDA label: SOMAVERT (BLA 021106)
- Pituitary 2021: Pituitary Society update to acromegaly management guidelines
Read the source
Common questions
Pegvisomant, answered plainly.
01What is Pegvisomant?+
A pegylated growth hormone receptor antagonist approved for acromegaly. It blocks the receptor rather than the hormone, which is the opposite mechanism to every secretagogue in this category, and it is the reason IGF-1 rather than GH is used to follow the response. It is also referred to as Somavert, B2036-PEG. It is listed here under Growth Hormone as educational reference, which is not a recommendation to use it.
02Is Pegvisomant FDA approved?+
FDA approved. The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
03What is the half-life of Pegvisomant?+
~60-138 h, subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is Pegvisomant stored and handled?+
Supplied as a lyophilized powder in a single-dose vial with its own diluent; refrigerated per its label. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
05What vial strengths of Pegvisomant are commonly sold?+
Commonly listed vial strengths are 10, 15, 20, 25, 30 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.
Related in Growth Hormone
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.